Shanghai Xuerong Biotechnology Co., Ltd. (SHE:300511)
China · Delayed Price · Currency is CNY 4.150
0.00 (0.00%)
At close: Oct 28, 2026
SHE:300511 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 2,339 | 1,966 | 2,133 | 2,534 | 2,291 | 2,045 |
Other Revenue | 21.87 | 21.87 | 29.86 | 30.84 | 29.29 | 28.25 |
| 2,361 | 1,988 | 2,162 | 2,565 | 2,320 | 2,073 | |
Revenue Growth | 27.89% | -8.09% | -15.70% | 10.55% | 11.93% | -5.86% |
Cost of Revenue | 1,974 | 1,733 | 2,129 | 2,409 | 2,102 | 2,024 |
Gross Profit | 387.07 | 254.57 | 33.76 | 156.48 | 218.31 | 49.16 |
Selling, General & Admin | 162.34 | 158.58 | 165.77 | 240.52 | 135.89 | 155.27 |
Research & Development | 4.12 | 3.34 | 3.46 | 6.84 | 7.49 | 13.56 |
Other Operating Expenses | 18.24 | 20.38 | 20.05 | 20.54 | 18.83 | 16.69 |
Operating Expenses | 185.22 | 183.02 | 195.3 | 270.7 | 164.83 | 183.3 |
Operating Income | 201.86 | 71.55 | -161.54 | -114.23 | 53.48 | -134.14 |
Interest Expense | -15.08 | -60.68 | -98.21 | -88.77 | -92.96 | -77.11 |
Interest & Investment Income | 0.4 | 1.66 | 2.47 | 8.27 | 18.43 | 7.49 |
Currency Exchange Gain (Loss) | 4.03 | 4.03 | 1.44 | 1.29 | 3.77 | -6.11 |
Other Non Operating Income (Expenses) | -41.01 | -0.68 | -1.39 | -4.71 | 7.68 | -0.81 |
EBT Excluding Unusual Items | 150.2 | 15.88 | -257.22 | -198.15 | -9.6 | -210.68 |
Gain (Loss) on Sale of Investments | 0.04 | 0.04 | -0.65 | -3.76 | -5.55 | - |
Gain (Loss) on Sale of Assets | 3.64 | 16.31 | 7.85 | 0.5 | -9.1 | -22.7 |
Asset Writedown | -114.41 | -1.23 | -377.84 | - | -364.16 | -139.17 |
Other Unusual Items | 6.38 | 8.19 | 11.45 | 9.32 | 7.86 | 16.91 |
Pretax Income | 45.85 | 39.19 | -616.41 | -192.1 | -380.55 | -355.65 |
Income Tax Expense | 0.25 | 0.78 | 0 | 0.24 | 13.57 | -4.49 |
Earnings From Continuing Operations | 45.6 | 38.42 | -616.41 | -192.33 | -394.12 | -351.15 |
Minority Interest in Earnings | -0.85 | -8.62 | -0.66 | 4.27 | 106.89 | 39.56 |
Net Income | 44.75 | 29.79 | -617.07 | -188.06 | -287.23 | -311.59 |
Net Income to Common | 44.75 | 29.79 | -617.07 | -188.06 | -287.23 | -311.59 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 679 | 596 | 498 | 495 | 487 | 433 |
Shares Outstanding (Diluted) | 679 | 596 | 498 | 495 | 487 | 433 |
Shares Change | 23.27% | 19.74% | 0.55% | 1.66% | 12.49% | -0.46% |
EPS (Basic) | 0.07 | 0.05 | -1.24 | -0.38 | -0.59 | -0.72 |
EPS (Diluted) | 0.07 | 0.05 | -1.24 | -0.38 | -0.59 | -0.72 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | 212 | 336.26 | 109.74 | -739.19 | 47.66 | -393.13 |
Free Cash Flow Per Share | 0.31 | 0.56 | 0.22 | -1.49 | 0.10 | -0.91 |
Gross Margin | 16.39% | 12.81% | 1.56% | 6.10% | 9.41% | 2.37% |
Operating Margin | 8.55% | 3.60% | -7.47% | -4.45% | 2.31% | -6.47% |
Profit Margin | 1.90% | 1.50% | -28.54% | -7.33% | -12.38% | -15.03% |
Free Cash Flow Margin | 8.98% | 16.92% | 5.08% | -28.82% | 2.05% | -18.96% |
EBITDA | 513.34 | 408.19 | 208.62 | 206.93 | 393.25 | 178.2 |
EBITDA Margin | 21.74% | 20.54% | 9.65% | 8.07% | 16.95% | 8.60% |
D&A For EBITDA | 311.49 | 336.63 | 370.16 | 321.16 | 339.77 | 312.33 |
EBIT | 201.86 | 71.55 | -161.54 | -114.23 | 53.48 | -134.14 |
EBIT Margin | 8.55% | 3.60% | -7.47% | -4.45% | 2.31% | -6.47% |
Effective Tax Rate | 0.53% | 1.98% | - | - | - | - |
Revenue as Reported | 662.68 | 1,988 | 2,162 | 2,565 | 2,320 | 2,073 |
Advertising Expenses | - | 2.42 | 2.43 | 14.25 | 2 | 1.93 |